Rifaximin Alleviates MASH by Suppressing Deoxycholic Acid-Triggered Macrophage-Hepatocyte Dialogue

Authors:
  • MNMei-Tong Nie
    Mei-Tong Nie
  • CYChuan Yin
    Chuan Yin
  • HYHai-Liang Yuan
    Hai-Liang Yuan
  • LCLi-Lin Chen
    Li-Lin Chen
  • PSPei-Mei Shi
    Pei-Mei Shi
  • JCJia-Rong Cai
    Jia-Rong Cai
  • ZYZi-Wei Yan
    Zi-Wei Yan
  • JZJing-Yi Zhu
    Jing-Yi Zhu
  • QLQian-Ting Li
    Qian-Ting Li
  • FCFei Chen
    Fei Chen
  • HXHai-Lin Xiong
    Hai-Lin Xiong
  • SCShi-Lin Cheng
    Shi-Lin Cheng

Abstract
Rifaximin ameliorates metabolic dysfunction-associated steatohepatitis (MASH) in preclinical models; however, its underlying molecular mechanisms and therapeutic potential in the clinic remain incompletely defined. Here, we demonstrate that rifaximin alleviates MASH by reducing intestinal deoxycholic acid (DCA), a secondary bile acid that directly activates S1PR2 on MoMFs. DCA-S1PR2 signaling promotes MoMF recruitment to steatotic livers and induces secretion of MD-1 that suppresses hepatocyte Hnf1α through activation of TLR4. The therapeutic efficacy of rifaximin is dependent on restoration of hepatic Hnf1α expression, whereas hepatocyte Hnf1α deficiency perpetuates a feed-forward loop of Ccl2-driven MoMF recruitment. In a proof-of-concept clinical trial, rifaximin treatment led to rapid and progressive improvements in hepatic steatosis in patients with MASLD. Therapeutic responses were correlated with the reductions in fecal and serum DCA levels and circulating MD-1. Our findings define a pathogenic DCA-driven macrophage-hepatocyte crosstalk underlying MASH progression and establish rifaximin as a promising, mechanism-based therapeutic strategy for MASH.